MiMedx Group, Inc.

Equities

MDXG

US6024961012

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-15 pm EDT 5-day change 1st Jan Change
6.35 USD -1.40% Intraday chart for MiMedx Group, Inc. -7.97% -27.59%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products MT
MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit DJ
MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation from FDA CI
MiMedx Group to Buy Distribution Rights for TELA Bio's Wound Care Product MT
MiMedx Launches E-Commerce Platform MT
Mimedx Introduces E-Commerce and Account Management Platform CI
Lake Street Starts MiMedx Group With Buy Rating, $12 Price Target MT
MiMedx Group, Inc. Announces Appointment of New Independent Directors CI
Mizuho Securities Raises Price Target on MiMedx to $14 From $13, Maintains Buy Rating MT
Spectral AI Names Peter Carlson Chief Executive Officer; Reaffirms 2024 Preliminary Revenue Guidance MT
Transcript : MiMedx Group, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (MDXG) MIMEDX GROUP Posts Q4 Revenue $86.8M, vs. Street Est of $85.2M MT
Earnings Flash (MDXG) MIMEDX GROUP Reports Q4 EPS $0.04, vs. Street Est of $0.06 MT
MiMedx Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
MiMedx Group, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing CI
MiMedx reports US FDA warning letter for Axiofill, shares drop RE
Stocks to Watch : MiMedx Group, Nokia DJ
MiMedx says US FDA's warning letter for Axiofill not related to safety RE
MiMedx Group Gets FDA Warning Letter on Axiofill Classification DJ
MiMedx Group Converts Series B Preferred Stock to Common Stock, Adds 30 Million Shares MT
Spectral AI Names Peter M. Carlson CFO MT
Mizuho Securities Adjusts MiMedx Price Target to $12 From $14, Maintains Buy Rating MT
MiMedx Group Swings to Q3 Profit, Revenue Rises; Shares Fall After Hours MT
Transcript : MiMedx Group, Inc., Q3 2023 Earnings Call, Oct 30, 2023
Chart MiMedx Group, Inc.
More charts
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.35 USD
Average target price
12.44 USD
Spread / Average Target
+95.85%
Consensus
  1. Stock Market
  2. Equities
  3. MDXG Stock
  4. News MiMedx Group, Inc.
  5. Mimedx : Wins Japan Regulatory Ok to Market Epifix